High Purity and Stable Quality
Chemical Name: Cisatracurium Besylate
CAS: 96946-42-8
Appearance: White or Almost White Powder, Odorless, Slightly Hygroscopic
Assay: 95.0%~102.0% (C65H82N2O18S2 on the dried basis)
| Chemical Name | Cisatracurium Besylate |
| CAS Number | 96946-42-8 |
| CAT Number | RF-API13 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C53H72N2O12.2C6H5O3S |
| Molecular Weight | 1243.49 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White or Almost White Powder, Odorless, Slightly Hygroscopic |
| Solubility | Freely soluble in dichloromethane, acetonitrile, slight soluble in water |
| Specific Rotation | -35°~-45° (C=10mg/ml, 0.1mg/ml benzene sulfonic acid) |
| Identification | Dissolve with dilute hydrochoric acid, dropwise dilute bismuth potassium iodide TS, yellow precipitations will be produced |
| Identification | 1. HPLC ; 2. I.R |
| Assay | 95.0~102.0% (C65H82N2O18S2 on the dried basis) |
| pH | 3.5~5.0 |
| Clarity & Color of the Solution | Should be Clear & Colorless |
| Loss on Drying | ≤2.0% |
| Residual on Ignition | ≤0.20% |
| Heavy Metals | ≤20ppm |
| Trans-Trans Isomer | ≤0.50% |
| Cis-Trans Isomer | ≤0.50% |
| Mono-quaternaries | ≤1.50% |
| Anyother Individual Impurity | ≤1.50% |
| Total Impurities | ≤5.0% |
| Optical Isomer SS-Isomer | ≤1.50% |
| Optical Isomer RS- Isomer | ≤1.00% |
| Sulfate | ≤50ppm |
| Ethyl | ≤0.50% |
| Acetone | ≤0.50% |
| Methanol | ≤0.3% |
| Dichloromethane | ≤0.06% |
| Acetonitrile | ≤0.041% |
| Methylbenzene | ≤0.089% |
| Residual Solvents Acetonitrile | ≤410ppm |
| Test Standard | Chinese Pharmacopoeia (CP) |
| Usage | Active Pharmaceutical Ingredient (API) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Cisatracurium besylate is the benzene sulfonate salt form of atracurium. It is a kind of artificially synthetic non-depolarizing muscle relaxants with its role similar as tubocurarine. It has an onset time of 1 minute and duration time of 15 minutes. The treatment dose does not affect the heart, liver and kidney function. It also has no accumulation property. It also can induce the release of histamine when used at large doses. For muscle relaxation or breathing control required in surgery, compared with current clinical major muscle-relaxing anesthetic drugs, cisatracurium besylate is not metabolized through liver or kidney, and has cardiovascular stability; its effect of muscle relaxation is 3 times as strong as atracurium without any cardiovascular side effects. Cisatracurium besylate is mainly applied to general anesthesia, and can be widely used in intubation, treating liver and kidney dysfunction, used in cardiovascular surgery and elderly and pediatric patients. Compared with atracurium, this product has no dose-dependent adverse effects of histamine release; however, the disadvantage is that patients with liver and kidney dysfunction should administrate with caution. Since 1996 for the first time when this drug has entered into market in UK, foreign countries have gradually applied it to replace vecuronium and atracurium as the mainstream of clinical muscle relaxants.
The mechanism of action of cisatracurium besylate is similar with that of tubocurarine chloride; but this product is a kind of non-depolarizing muscle relaxant drugs which is mainly used for blocking the transmission of nerve impulses, boost muscle relaxation and can release histamine; but it has a lower effect than tubocurarine alkaline; it is characterized by a rapid onset and a high muscle relaxant effect.